Last reviewed · How we verify
Macleods Pharmaceuticals Ltd — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| ABACAVIR, DOLUTEGRAVIR AND LAMIVUDINE | ABACAVIR, DOLUTEGRAVIR, LAMIVUDINE | marketed | Other |
Therapeutic area mix
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Macleods Pharmaceuticals Ltd:
- Macleods Pharmaceuticals Ltd pipeline updates — RSS
- Macleods Pharmaceuticals Ltd pipeline updates — Atom
- Macleods Pharmaceuticals Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Macleods Pharmaceuticals Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/macleods-pharmaceuticals-ltd. Accessed 2026-05-16.